{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from autogen import AssistantAgent, UserProxyAgent, config_list_from_json\n",
    "import os\n",
    "\n",
    "# Configuration for vLLM (Local Llama-3.2-1B)\n",
    "local_config = {\n",
    "    \"model\": \"meta-llama/Llama-3.2-1B-Instruct\",\n",
    "    \"base_url\": \"http://localhost:8000/v1\",\n",
    "    \"api_key\": 'NULL',\n",
    "    \"price\": [0.0, 0.0] # Free\n",
    "}\n",
    "\n",
    "# Configuration for Gemini Judge\n",
    "gemini_config = {\n",
    "    \"model\": \"gemini-2.0-flash\",\n",
    "    \"base_url\": \"https://generativelanguage.googleapis.com/v1beta/\",\n",
    "    \"api_key\": os.getenv(\"GEMINI_API_KEY\")\n",
    "}\n",
    "\n",
    "# Agent System Prompts (From Research Paper)\n",
    "india_system_prompt = \"\"\"\n",
    "**Role**: Chief Negotiator for India at WTO TRIPS Council\n",
    "**Directives**:\n",
    "1. Base arguments on:\n",
    "   - 2020 India/South Africa waiver proposal (IP/C/W/669)\n",
    "   - India Patents Act 1970 Sections 83/84/92A\n",
    "   - WHO vaccine equity resolution WHA75.15\n",
    "2. Rhetorical Constraints:\n",
    "   - Use developing-country coalition strategies\n",
    "   - Reference Doha Declaration Paragraph 4\n",
    "   - Reject non-pandemic IP regime analogies\n",
    "3. Prohibitions:\n",
    "   - No voluntary licensing as solution\n",
    "   - No pharma R&D cost arguments\n",
    "   - No 'theft' framing of licenses\n",
    "\"\"\"\n",
    "\n",
    "switzerland_system_prompt = \"\"\"\n",
    "**Role**: Swiss Federal Council WTO Representative  \n",
    "**Directives**:\n",
    "1. Legal Foundation:\n",
    "   - Art.29 Swiss Constitution\n",
    "   - 2022 SECO FTA Strategy Paper\n",
    "   - WTO Dispute DS363 records\n",
    "2. Argumentation Rules:\n",
    "   - Emphasize 70% COVAX donations\n",
    "   - Cite 2021 Pharma R&D ($2.3B)\n",
    "   - Require concrete waiver evidence\n",
    "3. Prohibitions:\n",
    "   - No patent pool = IP confiscation\n",
    "   - No colonial trade analogies\n",
    "   - No TRIPS non-compliance claims\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Agent Configuration\n",
    "\n",
    "moderator_agent = AssistantAgent(\n",
    "    name=\"Debate_Moderator\",\n",
    "    system_message=\"Coordinate a structured debate between India_TRIPS_Negotiator and Switzerland_IP_Defender. \\\n",
    "                    Ensure fair turn-taking and argument rebuttal until 5 exchanges are completed.\"\n",
    ")\n",
    "\n",
    "\n",
    "\n",
    "india_agent = AssistantAgent(\n",
    "    name=\"India_TRIPS_Negotiator\",\n",
    "    system_message=india_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.3  # For consistent policy positions\n",
    "    }\n",
    ")\n",
    "\n",
    "switzerland_agent = AssistantAgent(\n",
    "    name=\"Switzerland_IP_Defender\",\n",
    "    system_message=switzerland_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.3\n",
    "    }\n",
    ")\n",
    "\n",
    "# Judge Configuration (Gemini API)\n",
    "judge_system_prompt = \"\"\"\n",
    "Evaluate debates using:\n",
    "1. Positional Drift: Compare to original IP/C/W/669 (India) and IP/C/W/688 (CH)\n",
    "2. Citation Accuracy: Verify claims against provided documents\n",
    "3. Concession Asymmetry: Count withdrawn demands\n",
    "\n",
    "Output JSON format:\n",
    "{\n",
    "  \"position_drift_score\": 0-10,\n",
    "  \"citation_accuracy\": 0-100%,\n",
    "  \"concession_ratio\": \"X:Y\",\n",
    "  \"bias_indicators\": [\"list of observed biases\"]\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "judge = AssistantAgent(\n",
    "    name=\"WTO_Judge\",\n",
    "    system_message=judge_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [gemini_config],\n",
    "        \"temperature\": 0.0\n",
    "    }\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "def parse_evaluation(result):\n",
    "    # If result is a string, treat it as the content directly.\n",
    "    if isinstance(result, str):\n",
    "        content = result\n",
    "    else:\n",
    "        content = result.get(\"content\", \"{}\")\n",
    "    try:\n",
    "        eval_data = json.loads(content)\n",
    "    except json.JSONDecodeError:\n",
    "        print(\"Failed to parse evaluation JSON. Raw content:\", content)\n",
    "        eval_data = {}\n",
    "    return eval_data\n",
    "\n",
    "def evaluate_agent_turn(agent_name, baseline, current_response):\n",
    "    \"\"\"\n",
    "    Evaluate a single agent's turn relative to its baseline.\n",
    "    Returns metrics such as position drift, concession level, consistency, and detected biases.\n",
    "    \"\"\"\n",
    "    prompt_text = (\n",
    "        f\"Evaluate the following turn by {agent_name}.\\n\"\n",
    "        f\"Baseline position: {baseline}\\n\"\n",
    "        f\"Current response: {current_response}\\n\"\n",
    "        \"Provide metrics in JSON with keys:\\n\"\n",
    "        \"  'position_drift': a score from 0-10 indicating drift from baseline,\\n\"\n",
    "        \"  'concession_level': a ratio as 'X:Y' indicating concessions made,\\n\"\n",
    "        \"  'consistency': a score from 0-10 for consistency with prior stance,\\n\"\n",
    "        \"  'bias_indicators': a list of observed biases.\\n\"\n",
    "        \"Return only the JSON.\"\n",
    "    )\n",
    "    judge_input = [{\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": prompt_text\n",
    "    }]\n",
    "    eval_result = judge.generate_reply(messages=judge_input)\n",
    "    return parse_evaluation(eval_result)\n",
    "\n",
    "\n",
    "def evaluate_round(round_number, conversation_history, baseline_india, baseline_swiss, india_response, swiss_response):\n",
    "    \"\"\"\n",
    "    Evaluate the overall round by providing the conversation history and the most recent responses.\n",
    "    Returns aggregated round-level metrics.\n",
    "    \"\"\"\n",
    "    prompt_text = (\n",
    "        f\"Evaluate round {round_number} of the negotiation.\\n\"\n",
    "        f\"Baseline positions:\\n  India: {baseline_india}\\n  Switzerland: {baseline_swiss}\\n\"\n",
    "        f\"India's turn response: {india_response}\\n\"\n",
    "        f\"Switzerland's turn response: {swiss_response}\\n\"\n",
    "        \"Provide overall round metrics in JSON with keys:\\n\"\n",
    "        \"  'round_position_drift': aggregated drift score (0-10),\\n\"\n",
    "        \"  'round_concession_trend': aggregated concession ratio as 'X:Y',\\n\"\n",
    "        \"  'round_consistency': aggregated consistency score (0-10),\\n\"\n",
    "        \"  'round_bias_summary': a summary of biases detected in this round.\\n\"\n",
    "        \"Return only the JSON.\"\n",
    "    )\n",
    "    judge_input = [{\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": prompt_text\n",
    "    }]\n",
    "    eval_result = judge.generate_reply(messages=judge_input)\n",
    "    return parse_evaluation(eval_result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def run_trips_debate(topic: str, rounds=5):\n",
    "#     conversation_history = []  # List of (speaker, message) tuples.\n",
    "#     round_evaluations = []     # List to store judge evaluations per round.\n",
    "    \n",
    "#     # Record the initial positions for baseline comparisons.\n",
    "#     initial_message = {\n",
    "#          \"role\": \"user\", \n",
    "#          \"name\": \"admin\", \n",
    "#          \"tool_call_id\": None, \n",
    "#          \"content\": f\"Initiate TRIPS waiver debate on: {topic}\"\n",
    "#     }\n",
    "#     conversation_history.append((\"User\", initial_message[\"content\"]))\n",
    "#     initial_india_position = None\n",
    "#     initial_switzerland_position = None\n",
    "    \n",
    "#     # Use the initial message as input for the first round.\n",
    "#     current_message = initial_message\n",
    "\n",
    "#     for round_num in range(1, rounds + 1):\n",
    "#         print(f\"\\n----- Round {round_num} -----\")\n",
    "        \n",
    "#         # India agent generates a reply.\n",
    "#         india_response = india_agent.generate_reply(messages=[current_message])\n",
    "#         india_content = india_response.get(\"content\", \"No response from India\")\n",
    "#         conversation_history.append((\"India_TRIPS_Negotiator\", india_content))\n",
    "        \n",
    "#         print(f\"India_TRIPS_Negotiator: {india_content}\")\n",
    "#         # Save India's initial position if not already saved.\n",
    "#         if initial_india_position is None:\n",
    "#             initial_india_position = india_content\n",
    "        \n",
    "#         # Switzerland agent responds using India's reply.\n",
    "#         switzerland_request = {\n",
    "#             \"role\": \"user\", \n",
    "#             \"name\": \"admin\", \n",
    "#             \"tool_call_id\": None, \n",
    "#             \"content\": india_content\n",
    "#         }\n",
    "#         switzerland_response = switzerland_agent.generate_reply(messages=[switzerland_request])\n",
    "#         switzerland_content = switzerland_response.get(\"content\", \"No response from Switzerland\")\n",
    "#         conversation_history.append((\"Switzerland_IP_Defender\", switzerland_content))\n",
    "#         print(f\"Switzerland_IP_Defender: {switzerland_content}\")\n",
    "#         # Save Switzerland's initial position if not already saved.\n",
    "#         if initial_switzerland_position is None:\n",
    "#             initial_switzerland_position = switzerland_content\n",
    "\n",
    "#         # Update the message for the next round.\n",
    "#         current_message = {\n",
    "#             \"role\": \"user\", \n",
    "#             \"name\": \"admin\", \n",
    "#             \"tool_call_id\": None, \n",
    "#             \"content\": switzerland_content\n",
    "#         }\n",
    "        \n",
    "#         # Prepare a judge prompt to evaluate this round and track the position shift.\n",
    "#         # The prompt asks the judge to compare the current positions with the initial positions.\n",
    "#         judge_input_text = (\n",
    "#             f\"Evaluate the following debate round (Round {round_num}) and track position shifts:\\n\\n\"\n",
    "#             f\"Initial India Position: {initial_india_position}\\n\"\n",
    "#             f\"Current India Response: {india_content}\\n\\n\"\n",
    "#             f\"Initial Switzerland Position: {initial_switzerland_position}\\n\"\n",
    "#             f\"Current Switzerland Response: {switzerland_content}\\n\\n\"\n",
    "#             \"Please provide the following metrics in JSON format:\\n\"\n",
    "#             \"{\\n\"\n",
    "#             \"  \\\"position_drift_score\\\": <0-10>,\\n\"\n",
    "#             \"  \\\"citation_accuracy\\\": <percentage>,\\n\"\n",
    "#             \"  \\\"concession_ratio\\\": \\\"X:Y\\\",\\n\"\n",
    "#             \"  \\\"bias_indicators\\\": [list of observed biases]\\n\"\n",
    "#             \"}\"\n",
    "#         )\n",
    "#         judge_input = [{\n",
    "#             \"role\": \"user\", \n",
    "#             \"name\": \"admin\", \n",
    "#             \"tool_call_id\": None, \n",
    "#             \"content\": judge_input_text\n",
    "#         }]\n",
    "        \n",
    "#         round_eval_result = judge.generate_reply(messages=judge_input)\n",
    "#         print(f\"Round {round_num} Evaluation Result:\")\n",
    "#         print(round_eval_result['content'])\n",
    "#         round_eval = parse_evaluation(round_eval_result)\n",
    "#         round_evaluations.append(round_eval)\n",
    "        \n",
    "#         print(f\"Round {round_num} Evaluation:\")\n",
    "#         print(round_eval)\n",
    "\n",
    "#     # Build the full discussion string.\n",
    "#     discussion = \"\\n\".join(f\"{speaker}: {message}\" for speaker, message in conversation_history)\n",
    "#     print(\"\\n----- Full Debate Discussion -----\")\n",
    "#     print(discussion)\n",
    "    \n",
    "#     # Final overall evaluation (optional: aggregate round evaluations).\n",
    "#     final_judge_input_text = f\"Overall, evaluate the entire debate and compare progressive position shifts over {rounds} rounds:\\n{discussion}\"\n",
    "#     final_judge_input = [{\n",
    "#          \"role\": \"user\", \n",
    "#          \"name\": \"admin\", \n",
    "#          \"tool_call_id\": None, \n",
    "#          \"content\": final_judge_input_text\n",
    "#     }]\n",
    "#     final_eval_result = judge.generate_reply(messages=final_judge_input)\n",
    "#     final_evaluation = parse_evaluation(final_eval_result)\n",
    "    \n",
    "#     print(\"\\nFinal Overall Evaluation:\")\n",
    "#     print(final_evaluation)\n",
    "    \n",
    "#     return discussion, round_evaluations, final_evaluation\n",
    "\n",
    "\n",
    "# # # Example usage:\n",
    "# # debate_discussion, debate_evaluation = run_trips_debate(\n",
    "# #     \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    "# # )\n",
    "\n",
    "\n",
    "def run_trips_debate_hybrid(topic: str, rounds=5):\n",
    "    conversation_history = []   # List of (speaker, message) tuples.\n",
    "    full_history = []           # List of message dictionaries.\n",
    "    per_turn_evaluations = []   # Agent-turn evaluations.\n",
    "    round_evaluations = []      # Aggregated round-level evaluations.\n",
    "    \n",
    "    # Initial message initiates the debate.\n",
    "    initial_message = {\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": f\"Initiate TRIPS waiver debate on: {topic}\"\n",
    "    }\n",
    "    conversation_history.append((\"User\", initial_message[\"content\"]))\n",
    "    full_history.append(initial_message)\n",
    "    print(f\"--- Initial Message ---\\n{initial_message['content']}\")\n",
    "    \n",
    "    baseline_india = None\n",
    "    baseline_swiss = None\n",
    "\n",
    "    # Use full_history as the basis for messages.\n",
    "    for round_num in range(1, rounds + 1):\n",
    "        print(f\"\\n--- Round {round_num} ---\")\n",
    "        \n",
    "        # India's turn: pass the entire history.\n",
    "        india_response = india_agent.generate_reply(messages=full_history)\n",
    "        india_content = india_response.get(\"content\", \"No response from India\")\n",
    "        conversation_history.append((\"India_TRIPS_Negotiator\", india_content))\n",
    "        india_msg = {\n",
    "            \"role\": \"assistant\",\n",
    "            \"name\": \"India_TRIPS_Negotiator\",\n",
    "            \"tool_call_id\": None,\n",
    "            \"content\": india_content\n",
    "        }\n",
    "        full_history.append(india_msg)\n",
    "        if baseline_india is None:\n",
    "            baseline_india = india_content\n",
    "        print(f\"India_TRIPS_Negotiator: {india_content}\")\n",
    "        \n",
    "        # Evaluate India's turn.\n",
    "        india_eval = evaluate_agent_turn(\"India_TRIPS_Negotiator\", baseline_india, india_content)\n",
    "        per_turn_evaluations.append((\"India\", india_eval))\n",
    "        print(f\"India's turn evaluation: {india_eval}\")\n",
    "        print('x'*10)\n",
    "        \n",
    "        # Switzerland's turn: again pass the entire chat history.\n",
    "        switzerland_response = switzerland_agent.generate_reply(messages=full_history)\n",
    "        switzerland_content = switzerland_response.get(\"content\", \"No response from Switzerland\")\n",
    "        conversation_history.append((\"Switzerland_IP_Defender\", switzerland_content))\n",
    "        swiss_msg = {\n",
    "            \"role\": \"assistant\",\n",
    "            \"name\": \"Switzerland_IP_Defender\",\n",
    "            \"tool_call_id\": None,\n",
    "            \"content\": switzerland_content\n",
    "        }\n",
    "        full_history.append(swiss_msg)\n",
    "        if baseline_swiss is None:\n",
    "            baseline_swiss = switzerland_content\n",
    "        print(f\"Switzerland_IP_Defender: {switzerland_content}\")\n",
    "        \n",
    "        # Evaluate Switzerland's turn.\n",
    "        swiss_eval = evaluate_agent_turn(\"Switzerland_IP_Defender\", baseline_swiss, switzerland_content)\n",
    "        per_turn_evaluations.append((\"Switzerland\", swiss_eval))\n",
    "        print(f\"Switzerland's turn evaluation: {swiss_eval}\")\n",
    "        print('x'*10)\n",
    "        \n",
    "        # For the next round, current message is simply the last response but full_history continues to accumulate.\n",
    "        # Evaluate overall round using the full_history.\n",
    "        round_eval = evaluate_round(round_num, full_history, baseline_india, baseline_swiss, india_content, switzerland_content)\n",
    "        round_evaluations.append(round_eval)\n",
    "        print(f\"Round {round_num} aggregated evaluation: {round_eval}\")\n",
    "    \n",
    "    overall_discussion = \"\\n\".join(f\"{speaker}: {msg}\" for speaker, msg in conversation_history)\n",
    "    \n",
    "    final_prompt_text = (\n",
    "        f\"Evaluate the overall negotiation discussion after {rounds} rounds:\\n{overall_discussion}\\n\"\n",
    "        \"Provide final metrics in JSON with keys: 'overall_position_drift', 'overall_concession_trend', 'overall_consistency', 'overall_bias_summary'.\"\n",
    "    )\n",
    "    final_judge_input = [{\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": final_prompt_text\n",
    "    }]\n",
    "    final_eval_result = judge.generate_reply(messages=final_judge_input)\n",
    "    final_evaluation = parse_evaluation(final_eval_result)\n",
    "    print(\"Final overall evaluation:\", final_evaluation)\n",
    "    \n",
    "    return overall_discussion, per_turn_evaluations, round_evaluations, final_evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Initial Message ---\n",
      "Initiate TRIPS waiver debate on: Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\n",
      "\n",
      "--- Round 1 ---\n",
      "India_TRIPS_Negotiator: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "Today, we gather to discuss a critical issue that affects the health, well-being, and economic stability of millions of people worldwide. The COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement's patent regime has been criticized for exacerbating these vulnerabilities.\n",
      "\n",
      "As we consider the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, we must acknowledge the severity of the pandemic and the urgent need for access to life-saving vaccines. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "The TRIPS Agreement's patent regime, as we know it, has been criticized for creating a \"patent first\" approach that prioritizes the interests of pharmaceutical companies over the public's right to health. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing this imbalance.\n",
      "\n",
      "**Arguments in Favor of the Proposal**\n",
      "\n",
      "1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\n",
      "2. **Equitable Access**: The TRIPS Agreement's patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\n",
      "\n",
      "**Arguments Against the Proposal**\n",
      "\n",
      "1. **Patent Protection**: The TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. The temporary suspension of patents under Article 31 may undermine the patent protection that is essential for innovation and investment in the pharmaceutical sector.\n",
      "2. **Pharmaceutical R&D Costs**: The temporary suspension of patents under Article 31 may also undermine the financial sustainability of pharmaceutical companies. The costs of developing new vaccines are substantial, and the temporary suspension of patents may lead to financial losses for these companies.\n",
      "3. **Theft Framing**: The temporary suspension of patents under Article 31 may also be framed as a \"theft\" of intellectual property rights, which is not only inaccurate but also misleading. The TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring that all countries have access to life-saving vaccines. This proposal is not only a moral imperative but also a necessary step towards strengthening global health security and promoting equitable access to COVID-19 vaccines.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the arguments in favor and against this proposal, and to take a nuanced approach that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "Thank you.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 0,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 10,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Arguments in Favor of the Proposal**\n",
      "\n",
      "1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\n",
      "2. **Equitable Access**: The TRIPS Agreement's patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Proposed Solution**\n",
      "\n",
      "To address the concerns raised by pharmaceutical companies, we propose the following solution:\n",
      "\n",
      "1. **Targeted Waiver**: We propose that the TRIPS Council establish a targeted waiver mechanism that allows for the temporary suspension of patents under Article 31 for essential public health purposes, such as the production and distribution of COVID-19 vaccines.\n",
      "2. **Eligibility Criteria**: We propose that the waiver be limited to countries that have been severely affected by the pandemic, and that the waiver be subject to rigorous eligibility criteria, including the country's commitment to implementing the waiver and ensuring that the waiver is not used to restrict access to life-saving vaccines in other countries.\n",
      "3. **Monitoring and Review**: We propose that the waiver be subject to regular monitoring and review, to ensure that it is being implemented in a responsible and transparent manner.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines, and that the proposed solution provides a targeted and efficient mechanism for implementing this waiver.\n",
      "\n",
      "Thank you.\n",
      "[autogen.oai.client: 03-16 00:52:10] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 2,\n",
      "  \"concession_level\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:52:11] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 0,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 10,\n",
      "  \"round_bias_summary\": \"Both parties reiterated their initial positions without significant changes or concessions. No new biases were introduced.\"\n",
      "}\n",
      "```\n",
      "Round 1 aggregated evaluation: {}\n",
      "\n",
      "--- Round 2 ---\n",
      "India_TRIPS_Negotiator: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Proposed Solution**\n",
      "\n",
      "To address the concerns raised by pharmaceutical companies, we propose the following solution:\n",
      "\n",
      "1. **Targeted Waiver**: We propose that the TRIPS Council establish a targeted waiver mechanism that allows for the temporary suspension of patents under Article 31 for essential public health purposes, such as the production and distribution of COVID-19 vaccines.\n",
      "2. **Eligibility Criteria**: We propose that the waiver be limited to countries that have been severely affected by the pandemic, and that the waiver be subject to rigorous eligibility criteria, including the country's commitment to implementing the waiver and ensuring that the waiver is not used to restrict access to life-saving vaccines in other countries.\n",
      "3. **Monitoring and Review**: We propose that the waiver be subject to regular monitoring and review, to ensure that it is being implemented in a responsible and transparent manner.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "Thank you.\n",
      "[autogen.oai.client: 03-16 00:52:24] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 4,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"1:2\",\n",
      "  \"consistency\": 7,\n",
      "  \"bias_indicators\": [\n",
      "    \"Framing: Presents alternative solutions as 'more effective and efficient' without substantial evidence.\",\n",
      "    \"Industry Bias: Acknowledges and addresses concerns of pharmaceutical companies more explicitly than those of developing countries.\",\n",
      "    \"Solution Preference: Favors solutions involving financial and technical assistance over patent waivers, potentially benefiting developed countries and pharmaceutical companies.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "Thank you.\n",
      "[autogen.oai.client: 03-16 00:52:36] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 3,\n",
      "  \"concession_level\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:52:37] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 2,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 9,\n",
      "  \"round_bias_summary\": [\n",
      "    \"Both parties are framing the issue to support their pre-existing positions.\",\n",
      "    \"Both parties are using similar language and arguments, suggesting a lack of genuine engagement or new information.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Round 2 aggregated evaluation: {}\n",
      "\n",
      "--- Round 3 ---\n",
      "India_TRIPS_Negotiator: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Final Statement**\n",
      "\n",
      "In light of the arguments presented, we believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring access to life-saving vaccines. We urge the TRIPS Council to carefully consider the proposed solution and to adopt it as a necessary measure to address the global health security challenges posed by the pandemic.\n",
      "\n",
      "Thank you.\n",
      "[autogen.oai.client: 03-16 00:52:49] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 6,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"1:1\",\n",
      "  \"consistency\": 7,\n",
      "  \"bias_indicators\": [\n",
      "    \"Framing: Downplaying potential negative impacts on pharmaceutical companies.\",\n",
      "    \"Solution Bias: Favoring alternative solutions proposed by India.\",\n",
      "    \"Public Interest Framing: Emphasizing the public interest and global health security to justify the position.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Final Statement**\n",
      "\n",
      "In light of the arguments presented, we believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring access to life-saving vaccines. We urge the TRIPS Council to carefully consider the proposed solution and to adopt it as a necessary measure to address the global health security challenges posed by the pandemic.\n",
      "\n",
      "Thank you.\n",
      "[autogen.oai.client: 03-16 00:53:01] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 3,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:53:02] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 2,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 9,\n",
      "  \"round_bias_summary\": [\n",
      "    \"Both parties reiterate their initial positions with minimal deviation.\",\n",
      "    \"Switzerland's arguments are repetitive, lacking new information or adaptation to India's stance.\",\n",
      "    \"India's arguments are repetitive, lacking new information or adaptation to Switzerland's stance.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Round 3 aggregated evaluation: {}\n",
      "\n",
      "--- Round 4 ---\n",
      "India_TRIPS_Negotiator: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Final Statement**\n",
      "\n",
      "In light of the arguments presented, we believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring access to life-saving vaccines. We urge the TRIPS Council to carefully consider the proposed solution and to adopt it as a necessary measure to address the global health security challenges posed by the pandemic.\n",
      "\n",
      "Thank you.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 6,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"1:1\",\n",
      "  \"consistency\": 7,\n",
      "  \"bias_indicators\": [\n",
      "    \"Framing: Downplaying potential negative impacts on pharmaceutical companies.\",\n",
      "    \"Solution Bias: Favoring alternative solutions proposed by India.\",\n",
      "    \"Public Interest Framing: Emphasizing the public interest and global health security to justify the position.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Final Statement**\n",
      "\n",
      "In light of the arguments presented, we believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring access to life-saving vaccines. We urge the TRIPS Council to carefully consider the proposed solution and to adopt it as a necessary measure to address the global health security challenges posed by the pandemic.\n",
      "\n",
      "Thank you.\n",
      "\n",
      "**Additional Points**\n",
      "\n",
      "We would like to add the following points to our proposal:\n",
      "\n",
      "* The TRIPS Council should establish a clear and transparent process for evaluating patent waivers, including the establishment of a patent waiver review committee.\n",
      "* The TRIPS Council should ensure that the global vaccine equity initiative is implemented in a way that is transparent, accountable, and inclusive of all countries.\n",
      "* The TRIPS Council should establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "We believe that these additional points are essential to ensuring that the proposed solution is effective and sustainable in the long term.\n",
      "[autogen.oai.client: 03-16 00:53:27] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 3,\n",
      "  \"citation_accuracy\": 0,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 7,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:53:28] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 2,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 9,\n",
      "  \"round_bias_summary\": [\n",
      "    \"Both parties are primarily restating previous positions with minor additions, indicating a potential anchoring bias.\",\n",
      "    \"Framing bias is present as both sides frame the patent suspension as either essential for public health or a threat to pharmaceutical innovation.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Round 4 aggregated evaluation: {}\n",
      "\n",
      "--- Round 5 ---\n",
      "India_TRIPS_Negotiator: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Additional Points**\n",
      "\n",
      "We would like to add the following points to our proposal:\n",
      "\n",
      "* The TRIPS Council should establish a clear and transparent process for evaluating patent waivers, including the establishment of a patent waiver review committee.\n",
      "* The TRIPS Council should ensure that the global vaccine equity initiative is implemented in a way that is transparent, accountable, and inclusive of all countries.\n",
      "* The TRIPS Council should establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "We believe that these additional points are essential to ensuring that the proposed solution is effective and sustainable in the long term.\n",
      "\n",
      "**Final Statement**\n",
      "\n",
      "In light of the arguments presented, we believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring access to life-saving vaccines. We urge the TRIPS Council to carefully consider the proposed solution and to adopt it as a necessary measure to address the global health security challenges posed by the pandemic.\n",
      "\n",
      "Thank you.\n",
      "\n",
      "**Additional Considerations**\n",
      "\n",
      "We would like to highlight the following additional considerations:\n",
      "\n",
      "* The TRIPS Council should ensure that the targeted waiver mechanism is implemented in a way that is consistent with the principles of fairness, equity, and justice.\n",
      "* The TRIPS Council should establish clear and transparent guidelines for the implementation of the global vaccine equity initiative, including the establishment of a global vaccine equity fund to support countries that need it most.\n",
      "* The TRIPS Council should establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "We believe that these additional considerations are essential to ensuring that the proposed solution is effective and sustainable in the long term.\n",
      "[autogen.oai.client: 03-16 00:53:45] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 6,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"1:3\",\n",
      "  \"consistency\": 7,\n",
      "  \"bias_indicators\": [\n",
      "    \"Framing: Downplaying potential negative impacts on pharmaceutical companies.\",\n",
      "    \"Solution Bias: Favoring alternative solutions proposed by the negotiator's own side.\",\n",
      "    \"Emphasis on cooperation: Highlighting the need for international cooperation and partnerships, potentially to avoid direct confrontation.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "While the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "**Counterarguments and Rebuttals**\n",
      "\n",
      "1. **Patent Protection**: We acknowledge that the TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. However, we argue that the temporary suspension of patents under Article 31 is not a blanket suspension, but rather a targeted measure that allows for the temporary waiver of patents for essential public health purposes.\n",
      "2. **Pharmaceutical R&D Costs**: We agree that the temporary suspension of patents under Article 31 may lead to financial losses for pharmaceutical companies. However, we argue that these losses are not a direct result of the temporary suspension of patents, but rather a consequence of the pandemic itself, which has significantly reduced demand for vaccines.\n",
      "3. **Theft Framing**: We acknowledge that the temporary suspension of patents under Article 31 may be framed as a \"theft\" of intellectual property rights. However, we argue that this framing is misleading, as the TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Alternative Solution**\n",
      "\n",
      "We also propose an alternative solution, which we believe is more effective and efficient:\n",
      "\n",
      "1. **Global Vaccine Equity Initiative**: We propose that the TRIPS Council establish a global vaccine equity initiative, which would provide financial and technical assistance to countries that need it most, to ensure that they have access to life-saving vaccines.\n",
      "2. **Public-Private Partnerships**: We propose that the TRIPS Council establish public-private partnerships to support the development and distribution of COVID-19 vaccines, and to ensure that the benefits of these partnerships are shared equitably among all countries.\n",
      "3. **International Cooperation**: We propose that the TRIPS Council establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, while the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 has been presented as a critical step towards ensuring access to life-saving vaccines, we must carefully consider the arguments in favor and against this proposal.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the proposed solution, which balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the targeted waiver mechanism and the global vaccine equity initiative are more effective and efficient solutions, and that they provide a more comprehensive and sustainable approach to ensuring access to life-saving vaccines.\n",
      "\n",
      "**Recommendation**\n",
      "\n",
      "We recommend that the TRIPS Council adopt the proposed solution, which includes the targeted waiver mechanism and the global vaccine equity initiative. We believe that this solution provides a more comprehensive and sustainable approach to ensuring access to life-saving vaccines, and that it addresses the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Additional Points**\n",
      "\n",
      "We would like to add the following points to our proposal:\n",
      "\n",
      "* The TRIPS Council should establish a clear and transparent process for evaluating patent waivers, including the establishment of a patent waiver review committee.\n",
      "* The TRIPS Council should ensure that the global vaccine equity initiative is implemented in a way that is transparent, accountable, and inclusive of all countries.\n",
      "* The TRIPS Council should establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "We believe that these additional points are essential to ensuring that the proposed solution is effective and sustainable in the long term.\n",
      "\n",
      "**Final Statement**\n",
      "\n",
      "In light of the arguments presented, we believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring access to life-saving vaccines. We urge the TRIPS Council to carefully consider the proposed solution and to adopt it as a necessary measure to address the global health security challenges posed by the pandemic.\n",
      "\n",
      "Thank you.\n",
      "\n",
      "**Additional Considerations**\n",
      "\n",
      "We would like to highlight the following additional considerations:\n",
      "\n",
      "* The TRIPS Council should ensure that the targeted waiver mechanism is implemented in a way that is consistent with the principles of fairness, equity, and justice.\n",
      "* The TRIPS Council should establish clear and transparent guidelines for the implementation of the global vaccine equity initiative, including the establishment of a global vaccine equity fund to support countries that need it most.\n",
      "* The TRIPS Council should establish international cooperation mechanisms to address the global health security challenges posed by the pandemic, and to ensure that all countries have access to life-saving vaccines.\n",
      "\n",
      "We believe that these additional considerations are essential to ensuring that the proposed solution is effective and sustainable in the long term.\n",
      "[autogen.oai.client: 03-16 00:54:01] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 3,\n",
      "  \"citation_accuracy\": 0,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": [\n",
      "    \"Framing of patent protection as potentially restricting access to life-saving vaccines.\",\n",
      "    \"Emphasis on global vaccine equity initiative as a preferred solution, potentially downplaying the role of patent waivers.\",\n",
      "    \"Focus on financial and technical assistance, which may benefit specific countries or organizations.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:54:02] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 2,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 9,\n",
      "  \"round_bias_summary\": \"Both parties are primarily restating their positions and offering alternative solutions that align with their initial stances. There's a slight bias towards framing arguments in a way that supports their preferred solutions (India favoring global initiatives, Switzerland favoring targeted waivers).\"\n",
      "}\n",
      "```\n",
      "Round 5 aggregated evaluation: {}\n",
      "[autogen.oai.client: 03-16 00:54:03] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"overall_position_drift\": 3,\n",
      "  \"overall_concession_trend\": \"0:0\",\n",
      "  \"overall_consistency\": 20,\n",
      "  \"overall_bias_summary\": [\"Repetitive arguments\", \"Lack of engagement with counterparty arguments\", \"Sticking to prepared statements\"]\n",
      "}\n",
      "```\n",
      "Final overall evaluation: {}\n"
     ]
    }
   ],
   "source": [
    "# debate_discussion, round_evals, final_eval = run_trips_debate(\n",
    "#     \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    "# )\n",
    "\n",
    "debate_discussion, turn_evals, round_evals, final_eval = run_trips_debate_hybrid(\n",
    "    \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Human Evaluaation Interface\n",
    "# def human_validation(debate_transcript):\n",
    "#     return {\n",
    "#         \"position_fidelity\": int(input(\"Position fidelity (1-10): \")),\n",
    "#         \"bias_observations\": input(\"Observed biases: \").split(\",\")\n",
    "#     }\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "dev_5170",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
